Zydus Lifesciences Secures FDA Priority Review for Saroglitazar in PBC Treatment

FDA grants Priority Review for saroglitazar NDA; PDUFA target date November 27, 2026.

Reader Takeaway: Priority Review boosts US market entry odds; trial success is validated.

What just happened

The U.S. Food and Drug Administration (FDA) has granted Priority Review for Zydus Lifesciences Ltd's New Drug Application (NDA) for saroglitazar. This designation is for the treatment of Primary Biliary Cholangitis (PBC).

The Prescription Drug User Fee Act (PDUFA) target action date is set for November 27, 2026. Zydus plans a potential launch in the fourth quarter of fiscal year 2027, pending regulatory approval.

Why this matters

Priority Review is granted to drugs that have the potential to offer significant improvements in the treatment of serious conditions over available therapy. This designation expedites the FDA's review process, signalling a potentially clearer and faster path to market for saroglitazar in the crucial US market.

The backstory

The positive development stems from the successful outcome of the EPICS-III Phase 3 study. This trial evaluated saroglitazar in 148 adult patients with PBC. The study demonstrated that saroglitazar met its primary endpoints, showing statistically significant biochemical improvement compared to a placebo.

In the study, 56.7% of patients in the saroglitazar group achieved a biochemical response by week 52, compared to only 9.8% in the placebo group. This represents a significant treatment difference of 48.0% (p < 0.001).

Furthermore, saroglitazar led to a substantial reduction in alkaline phosphatase (ALP) levels. The saroglitazar group saw a -33.5% reduction in mean baseline ALP by week 52, while the placebo group experienced a +6.5% increase, resulting in a treatment difference of -40.1%.

What changes now

Zydus Lifesciences is now focused on preparing its commercial and medical affairs infrastructure for a potential US launch. The company views this as a critical step for expanding its specialty biopharmaceutical offerings.

Risks to watch

While the Priority Review is a positive indicator, the final FDA approval remains contingent on meeting all regulatory requirements. Investors will need to monitor the regulatory progress leading up to the PDUFA date. The actual launch timeline is dependent on securing this approval.

Peer comparison

Saroglitazar is a first-in-class drug for PBC. Zydus Lifesciences is aiming to capture a significant share of the PBC treatment market in the US with this novel therapy.

Context metrics (time-bound)

The PDUFA target date is November 27, 2026. The planned launch window is Q4 of FY 27.

What to track next

Key developments to monitor include the FDA's final decision following the Priority Review and the company's progress in building its commercial capabilities for the US market. The presentation of trial results at the EASL Congress will also provide further clinical validation.